The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event?
Abstract
The administration of the first dose of a novel pharmaceutical compound to humans is the culmination of many years of efforts by many people. There is often a feeling of relief that the compound has made it this far and a feeling of great optimism and anticipation. However, it also can be a time of great trepidation because it is the first opportunity to determine the accuracy of the projections of the compound’s efficacy, ADME (absorption, distribution, metabolism, and elimination) properties, and most important, safety in humans. The administration of the first dose to humans usually results in a celebration by the development project team, although the first few dose levels of the initial clinical trial are usually uneventful and not much can be learned regarding the compound’s efficacy, ADME properties, and safety due to the low doses used in these initial dose cohorts. This is particularly true for nononcology compounds that are typically evaluated first in normal healthy volunteers (NHV) who would be expected to derive no benefit from the compound and thus generally receive a first-in-human (FIH) dose that is not anticipated to have pharmacologic activity. Unfortunately, in some instances, things do not go as anticipated. Sometimes it is learned from these early dose cohorts that the projections of the pharmacokinetics (PK) of the compound are wrong, or that the compound will not be as efficacious in humans as in animals. Sometimes the compound is found to have a side-effect profile in humans that was not predicted from the animal toxicology studies. Usually such side effects are relatively benign, consisting of headaches, nausea, drowsiness and other nuisance events which would have been difficult to appreciate in animal studies. On very rare occasions, the side effects may be more severe and, even more rarely, life-threatening. One such example of the latter was the ‘‘TeGenero Incident’’ (Expert Group on Phase One Clinical Trials 2006; Gambrill 2006). Serious, life-threatening adverse events were observed in all dosed subjects after the administration of TGN1412, a new class of monoclonal antibody (mAb) with a stimulatory mode of action on a subset of T cells known as regulatory T cells (Tregs; Expert Group on Phase One Clinical Trials 2006). This antibody was a humanized IgG4k mAb that was derived from the precursor mouse mAb 5.11A1 by grafting of the complementarity-determining regions (CDR). TGN1412 binds to CD28 and activates T cells without need for T cell receptor (TCR) preactivation, resulting in polyclonal T cell expansion and activation and concentration-dependent IL-2 production. As such, TGN1412 was termed a ‘‘superagonist.’’ The intent was to develop TGN1412 as a treatment for B cell chronic lymphocytic leukemia, in which T cells are deficient, and for autoimmune diseases, such as rheumatoid arthritis, in which Treg cell expansion might be beneficial. The TeGenero incident spurred a subsequent investigation by an expert scientific group (ESG) on Phase 1 Clinical Trials, appointed by the Medicines and Healthcare Products Regulatory Agency (MHRA) and under the leadership of Professor Gordon Duff, which culminated in a report known as ‘‘the Duff Report.’’ The objective of this article is to review the TeGenero incident and the Duff Report and to comment on whether the TeGenero incident was predictable and/or avoidable. Address correspondence to: Christopher Horvath, DVM, MS, DACVP, Vice President, PreClinical Sciences, Taligen Therapeutics, Cambridge, MA 02142; e-mail: chorvath@taligentherapeutics.com. Abbreviations: ABPI, Association of the British Pharmaceutical Industry; ADME, Absorption, Distribution, Metabolism, and Excretion; BBC, British Broadcasting Company; BIA, BioIndustry Association; CBER, FDA Center for Biologics Evaluation and Research; CD, cluster of differentiation; CDER, FDA Center for Drug Evaluation and Research; CDR, complementaritydetermining region; CHM, Commission on Human Medicines; CHMP, Committee for Medicinal Products for Human Use; CPMP, Committee for Proprietary Medicinal Products; CRS, cytokine release syndrome; CTA, clinical trial authorization; DIC, disseminated intravascular coagulation; DLT, doselimiting toxicity; EAG, expert advisory group; Emax, maximum effect; EMEA, European Medicines Agency; ESG, Expert Scientific Group on Phase 1 Clinical Trials; EU, European Union; EUDRA, European Drug Regulatory Authorities; Fc, Fragment, crystallizable; FcR, Fc receptor; FcRn, neonatal Fc receptor; FDA, Food and Drug Administration; FIH, first-in-human; FOI, Freedom of Information; HED, human equivalent dose; HNSTD, highest nonseverely toxic dose; IB, Investigator’s Brochure; IgG, immunoglobulin isotype G; IL2, Interleukin–2; IMPD, Investigational Medicinal Product Dossier; IND, Investigational New Drug; mAb, monoclonal antibody; MABEL, minimum anticipated biological effect (dose) level; MHRA, Medicines and Healthcare Products Regulatory Agency; MOA, mechanism of ac
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They mentioned that the severe reactions were as a result of unexpected biological effect of the drug.[9]”
From TGN1412: From Discovery to Disaster (2010) · cites this paper as [9]
In the citing paper
“They did not find any flaw in trial procedure or in manufacture of drug.”
From TGN1412: From Discovery to Disaster (2010) · cites this paper as [9]
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“In an excellent review, Tabrizi and Roskos point out that appropriate preclinical safety testing of mAbs is usually highly predictive of human clinical PK, PD, and safety (Tabrizi and Roskos 2007).”
BackgroundBaber, N. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb05705.x · Cited by 759
OKT3: A monoclonal anti-human T lymphocyte antibody with potent mitogenic properties
Van Wauwe, J. P., DeMay, J. R., & Goossens, J. G. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.5.2359.a · Cited by 711
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.
Van Wauwe, J. P., De Mey, J. R., & Goossens, J. G. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.124.6.2708 · Cited by 582
Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316 · cited 3×
“Within ninety minutes, those who had received TGN1412 had a systemic inflammatory response that was characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgia, nausea, diarrhea, erythema, vasodilatation, and hypotension (Suntharalingam et al. 2006).”
BackgroundResultInfluentialWing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
First dose of potential new medicines to humans: how animals help
Greaves, P., Williams, A., & Eve, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1329 · Cited by 243
Ward, K. W., & Smith, B. R. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.603 · Cited by 212
Loss of Siglec expression on T lymphocytes during human evolution
Nguyen, D. H., Hurtado-Ziola, N., Gagneux, P., & Varki, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510484103 · Cited by 204
Research works printed but not linked: 21
- Alegre ML, 1990, Transplant Proc, 22, 1920
- Association of the British Pharmaceutical Industry and BioIndustry Association (APBI/BIA), 1977, Guidelines for preclinical testing on new medicinal products. Parts 1 and 2
- Association of Food and Drug Officials (AFDO), 1959, Appraisal of the safety of chemicals in food, drugs and cosmetics
- BioSafe General Membership Meeting, 2008, Cytokine release assays: Current approaches and considerations
- Chatenoud L, 1990, Transplant Proc, 22, 2605
- Early Stage Clinical Trial Taskforce, 2007, Early Stage Clinical Trial Taskforce–Joint ABPI/BIA report
- European Medicines Agency (EMEA), 2004, Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose
- European Medicines Agency (EMEA), 2007, EMEA guidance for companies requesting scientific advice or protocol assistance
- Expert Group on Phase One Clinical Trials (chairman: Professor Gordon W. Duff), 2006, Expert group on phase one clinical trials: Final report
- FDA CDER Immunotoxicology Subcommittee Meeting, 2008, Cytokine release: What does it mean to you?
- FDA Science Board, Subcommittee on Science and Technology, 2007, FDA science and mission at risk
- Gibb F, 2008, The Times
- Hale G, 1983, Mol Biol Med, 1, 321
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)ICH harmonised tripartite guideline Statistical principles for clinical trials. E91998(accessed March 28, 2008)http://www.ich.org/LOB/media/MEDIA485.pdf
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)ICH harmonised tripartite guideline. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. M3(R2). Step 22008aJuly15(accessed August 21, 2008)http://www.ich.org/LOB/media/MEDIA4744.pdf
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)2008b(accessed August 21, 2008)ICH Steering Committee meeting. Monitoring and Protecting the Global Public HealthMay 31–June 5Portland, Oregon, USAhttp://www.ich.org/cache/compo/276-254-1.html
- Medicines and Healthcare Products Regulatory Agency (MHRA), 2006, Investigations into adverse incidents during clinical trials of TGN1412 (interim report)
- Royal Statistical Society (RSS), 2007, Report of the working party on statistical issues in first-in-man studies
- Sims J, 2007, Calculation of the minimum anticipated biological effect level (MABEL) and 1st dose in humans, in EMEA Workshop on the Guideline for First-in-Man Clinical Trials for potential high-risk medicinal products
- U.S. Food and Drug Administration (FDA), 2005, Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers
- U.S. Food and Drug Administration (FDA), 2005, Guidance for industry, investigators, and reviewers: Exploratory IND studies (Draft)
Cited by
TGN1412: From Discovery to Disaster
Attarwala, H. (2010) · Journal of Young Pharmacists · doi:10.4103/0975-1483.66810 · Cited by 253
“They mentioned that the severe reactions were as a result of unexpected biological effect of the drug.[9] Deficiencies they found in the drug trail were inadequate maintenance medical records, physician with inappropriate qualification, inadequacy in ensuring insurance protection of the sponsor, and failure in arrangi…”
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges
Vugmeyster, Y. (2012) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v3.i4.73 · Cited by 242
Pharmacovigilance: An Overview
Beninger, P. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.07.012 · Cited by 178
van Gerven, J., & Bonelli, M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13550 · Cited by 162
Muller, P. Y., Milton, M., Lloyd, P. M., Sims, J., & Brennan, F. R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.013 · Cited by 152
Self-citation
Metadata
- Authors
- Horvath, C. J., & Milton, M. N.
- Affiliations
- Taligen Therapeutics, Cambridge, Massachusetts 02142, USA
- Tempo Pharmaceuticals, Cambridge, Massachusetts 02142, USA
- Corresponding author
- Horvath, Christopher J.
- Venue
- Toxicologic Pathology
- Publisher
- SAGE Publications
- Published
- 2009-02-24
- Volume
- 37
- Issue
- 3
- Pages
- 372-383
- ISSN
- 0192-6233 (ISSN-L)
- 1533-1601
- OpenAlex
- W2122348862
- Cited by
- 87
- References
- 45
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 6 · 2019: 1 · 2018: 11 · 2017: 2 · 2016: 6 · 2015: 4 · 2014: 5 · 2013: 8 · 2012: 4
- FWCI
- 9.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Toxicologic Pathology (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- TGN1412, monoclonal antibodies, regulatory T cells, CD28, T cell activation, adverse drug reactions, drug safety, healthy volunteers, pharmacokinetics, pharmacodynamics
- MeSH terms
- Antibodies, Monoclonal, Health Planning Guidelines, Humans, Lymphocyte Activation, Pharmacokinetics, Pharmacology, Leukemia, Lymphocytic, Chronic, B-Cell, Clinical Trials, Phase I as Topic, CD28 Antigens, Antibodies, Monoclonal, Humanized, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event? https://app.cochat.ai/papers/10.1177/0192623309332986
- The paper
- Horvath, C. J., & Milton, M. N. (2009). The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event? Toxicologic Pathology. https://doi.org/10.1177/0192623309332986
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.